Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.40 |
| ▸ | DNM2 | P50570 | 6/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798265 | 0.94 | SLC29A1 (0.43) | SLC29A1CYP1A2GAACYP2C19L3MBTL1 | |
| SCHEMBL6641031 | 0.90 | SLC29A1 (0.51) | SLC29A1CA1CA2CA9DNM2 | |
| SCHEMBL6716597 | 0.88 | SLC29A1 (0.50) | SLC29A1CA1CA2CA9DNM2 | |
| SCHEMBL6720244 | 0.86 | SLC29A1 (0.51) | SLC29A1CA1CA2CA9DNM2 | |
| SCHEMBL7776204 | 0.85 | SLC29A1 (0.50) | SLC29A1DNM2CRHR1KCNH3KMT2A | |
| SCHEMBL7774646 | 0.85 | SLC29A1 (0.50) | SLC29A1DNM2CRHR1KCNH3KMT2A | |
| SCHEMBL2370354 | 0.83 | SLC29A1 (0.49) | SLC29A1TLR8CRHR1KMT2ASMN1; SMN2 | |
| SCHEMBL7535691 | 0.81 | TP53 (0.46) | SLC29A1CYP1A2GAACYP2C19L3MBTL1 | |
| SCHEMBL12373453 | 0.81 | TLR8 (0.51) | SLC29A1CA1CA2CA9TLR8 | |
| SCHEMBL1274425 | 0.81 | HRH3 (0.37) | SLC29A1CYP1A2GAACYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078961-A1 | TRIAZINE COMPOUND AND USE THEREOF | PEPTOIDE CO.,LTD. (KR) | 2021-03-18 | — | — | US | disclosed |
| WO-2019190131-A1 | TRIAZINE COMPOUND AND USE THEREOF | 정하윤 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078961-A1 | TRIAZINE COMPOUND AND USE THEREOF | TLR5, IL5, TLR2 | SLC29A1 3848/4885CYP1A2 332/4885GAA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.